Fig. 6
From: Stem cell phenotype predicts therapeutic response in glioblastomas with MGMT promoter methylation
Stratification by CD133 expression reveals that MGMT promoter methylation is a predictor of progression-free survival (PFS) and overall survival (OS) by Kaplan–Meier analysis only in patients with high CD133 levels. In patients with low CD133 expression (raw score, product of intensity and percentage of cells, ≤ 100), there was no-significant difference in survival between those with methylated MGMT and those with unmethylated MGMT. (Methylated, green; Unmethylated, blue, N = number of patients at time 0, Median survival (Med) is in months; PFS-progression free survival, OS-overall survival)